Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,141 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of Maze Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.36, for a total value of $425,476.76. Following the sale, the chief marketing officer directly owned 16,141 shares of the company’s stock, valued at $425,476.76. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $25.87 on Friday. Maze Therapeutics, Inc. has a 52 week low of $14.16 and a 52 week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm’s 50-day simple moving average is $28.74 and its 200 day simple moving average is $31.20. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -10.27 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, sell-side analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the fourth quarter valued at about $43,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the second quarter valued at about $48,000. Finally, Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the last quarter.

Analysts Set New Price Targets

MAZE has been the topic of a number of analyst reports. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.